• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[3H]A-317491,一种新型高亲和力非核苷酸拮抗剂,可特异性标记人P2X2/3和P2X3受体。

[3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptors.

作者信息

Jarvis Michael F, Bianchi Bruce, Uchic John T, Cartmell Jayne, Lee Chih-Hung, Williams Michael, Faltynek Connie

机构信息

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois, USA.

出版信息

J Pharmacol Exp Ther. 2004 Jul;310(1):407-16. doi: 10.1124/jpet.103.064907. Epub 2004 Mar 15.

DOI:10.1124/jpet.103.064907
PMID:15024037
Abstract

A-317491 is a potent and selective antagonist of P2X3 and P2X(2/3) receptors. In the present studies, the ability of [3H]A-317491 to label recombinant human P2X(2/3) and P2X(3) receptors was characterized. Using membranes prepared from 1321N1 cells expressing P2X(2/3) receptors, [3H]A-317491 specifically labeled high-affinity (Kd = 0.9 nM) recognition sites. High-affinity [3H]A-317491 binding was not detected in membrane preparations from native 1321N1 cells or cells expressing homomeric P2X1, P2X2, or P2X3 receptors. Specific [3H]A-317491 P2X3 receptors could only be reliably detected following treatment of intact P2X3 receptor-expressing cells with apyrase (1 U/ml) both before and during membrane preparation. Under these conditions, [3H]A-317491 also labeled high-affinity (Kd = 9 nM) binding sites. Lower affinity binding components (Kd values of 87-790 nM) were detected in both assays using higher ligand concentrations that likely represent nonfunctional recognition sites. [3H]A-317491 binding to both P2X(2/3) and P2X3 receptors was reversible, and ligand kinetic studies provided similar estimates of the high-affinity binding constants. Potent P2X3 receptor agonists 2-methylthio-ATP, 2,3-O-(4-benzoylbenzoyl)-ATP, and alpha,beta-methylene adenosine triphosphate also potently inhibited specific [3H]A-317491 binding to both P2X(2/3) and P2X3 receptors. The pharmacological profile for P2X receptor antagonists to inhibit [3H]A-317491 binding to P2X(2/3) and P2X3 receptors was highly correlated (r = 0.98, P < 0.05), and a similar rank order of potency was observed for blockade of P2X(2/3) receptor-mediated calcium influx. These data demonstrate that [3H]A-317491 is the first useful radioligand for the specific labeling of P2X3-containing channels.

摘要

A - 317491是一种强效且具有选择性的P2X3和P2X(2/3)受体拮抗剂。在本研究中,对[3H]A - 317491标记重组人P2X(2/3)和P2X(3)受体的能力进行了表征。使用从表达P2X(2/3)受体的1321N1细胞制备的膜,[3H]A - 317491特异性标记高亲和力(Kd = 0.9 nM)识别位点。在天然1321N1细胞或表达同聚体P2X1、P2X2或P2X3受体的细胞制备的膜中未检测到高亲和力的[3H]A - 317491结合。只有在膜制备之前和过程中用腺苷双磷酸酶(1 U/ml)处理完整的表达P2X3受体的细胞后,才能可靠地检测到特异性的[3H]A - 317491与P2X3受体的结合。在这些条件下,[3H]A - 317491也标记了高亲和力(Kd = 9 nM)结合位点。在两种测定中,使用较高的配体浓度检测到较低亲和力的结合成分(Kd值为87 - 790 nM),这些可能代表无功能的识别位点。[3H]A - 317491与P2X(2/3)和P2X3受体的结合是可逆的,配体动力学研究提供了相似的高亲和力结合常数估计值。强效的P2X3受体激动剂2 - 甲硫基 - ATP、2,3 - O - (4 - 苯甲酰苯甲酰基) - ATP和α,β - 亚甲基三磷酸腺苷也能有效抑制特异性的[3H]A - 317491与P2X(2/3)和P2X3受体的结合。P2X受体拮抗剂抑制[3H]A - 317491与P2X(2/3)和P2X3受体结合的药理学特征高度相关(r = 0.98,P < 0.05),并且在阻断P2X(2/3)受体介导的钙内流方面观察到了相似的效价顺序。这些数据表明,[3H]A - 317491是第一个用于特异性标记含P2X3通道的有用放射性配体。

相似文献

1
[3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptors.[3H]A-317491,一种新型高亲和力非核苷酸拮抗剂,可特异性标记人P2X2/3和P2X3受体。
J Pharmacol Exp Ther. 2004 Jul;310(1):407-16. doi: 10.1124/jpet.103.064907. Epub 2004 Mar 15.
2
[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.[3H]A-804598([3H]2-氰基-1-[(1S)-1-苯乙基]-3-喹啉-5-基胍)是一种新型、强效且选择性的P2X7受体拮抗剂放射性配体。
Neuropharmacology. 2009 Jan;56(1):223-9. doi: 10.1016/j.neuropharm.2008.06.012. Epub 2008 Jun 17.
3
A comparison of the binding characteristics of recombinant P2X1 and P2X2 purinoceptors.重组P2X1和P2X2嘌呤受体结合特性的比较。
Br J Pharmacol. 1996 Aug;118(7):1806-12. doi: 10.1111/j.1476-5381.1996.tb15607.x.
4
2', 3'-O-(2,4,6,trinitrophenyl)-ATP and A-317491 are competitive antagonists at a slowly desensitizing chimeric human P2X3 receptor.2',3'-O-(2,4,6-三硝基苯基)-ATP和A-317491是一种缓慢脱敏的嵌合型人P2X3受体的竞争性拮抗剂。
Br J Pharmacol. 2003 Sep;140(1):202-10. doi: 10.1038/sj.bjp.0705411. Epub 2003 Jul 29.
5
Flexible subunit stoichiometry of functional human P2X2/3 heteromeric receptors.功能性人源P2X2/3异源寡聚体受体的灵活亚基化学计量比
Neuropharmacology. 2015 Dec;99:115-30. doi: 10.1016/j.neuropharm.2015.07.008. Epub 2015 Jul 13.
6
A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat.A-317491是一种新型的强效且选择性的P2X3和P2X2/3受体非核苷酸拮抗剂,可减轻大鼠的慢性炎症性疼痛和神经性疼痛。
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17179-84. doi: 10.1073/pnas.252537299. Epub 2002 Dec 13.
7
Characterization of cultured dorsal root ganglion neuron P2X receptors.培养的背根神经节神经元P2X受体的特性分析。
Eur J Neurosci. 1999 Jan;11(1):149-54. doi: 10.1046/j.1460-9568.1999.00426.x.
8
High affinity P2x-purinoceptor binding sites for [35S]-adenosine 5'-O-[3-thiotriphosphate] in rat vas deferens membranes.大鼠输精管膜中[35S]-腺苷5'-O-[3-硫代三磷酸]的高亲和力P2x嘌呤受体结合位点。
Br J Pharmacol. 1996 Jan;117(1):63-70. doi: 10.1111/j.1476-5381.1996.tb15155.x.
9
Endogenous opioid mechanisms partially mediate P2X3/P2X2/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain.内源性阿片机制部分介导了炎症性疼痛和化学性疼痛大鼠模型中与P2X3/P2X2/3相关的抗伤害感受,但在神经性疼痛中并非如此。
Br J Pharmacol. 2005 Sep;146(2):180-8. doi: 10.1038/sj.bjp.0706346.
10
Competitive antagonism of recombinant P2X(2/3) receptors by 2', 3'-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP).2',3'-O-(2,4,6-三硝基苯基)腺苷5'-三磷酸(TNP-ATP)对重组P2X(2/3)受体的竞争性拮抗作用。
Mol Pharmacol. 2000 Dec;58(6):1502-10. doi: 10.1124/mol.58.6.1502.

引用本文的文献

1
Radioligands Targeting the Purinergic P2X Receptors.靶向嘌呤能P2X受体的放射性配体
Cells. 2025 Jun 27;14(13):984. doi: 10.3390/cells14130984.
2
Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist.氚标记变构 P2X4 受体拮抗剂的制备及初步评价。
Purinergic Signal. 2024 Dec;20(6):645-656. doi: 10.1007/s11302-024-10005-2. Epub 2024 May 25.
3
Migraine Treatment: Towards New Pharmacological Targets.偏头痛治疗:寻求新的药物靶点。
Int J Mol Sci. 2023 Jul 31;24(15):12268. doi: 10.3390/ijms241512268.
4
Neurotropin alleviates rat osteocarcinoma pain via PX receptor activation in the midbrain periaqueductal gray.神经妥乐平通过激活中脑导水管周围灰质中的 PX 受体减轻大鼠骨肉瘤疼痛。
Iran J Basic Med Sci. 2021 Oct;24(10):1395-1403. doi: 10.22038/IJBMS.2021.57965.12904.
5
Coordinated calcium signalling in cochlear sensory and non-sensory cells refines afferent innervation of outer hair cells.协调耳蜗感觉和非感觉细胞中的钙信号传递可改善传入纤维对外毛细胞的支配。
EMBO J. 2019 May 2;38(9). doi: 10.15252/embj.201899839. Epub 2019 Feb 25.
6
The role of purinergic signaling in the etiology of migraine and novel antimigraine treatment.嘌呤能信号在偏头痛病因及新型抗偏头痛治疗中的作用
Purinergic Signal. 2015 Sep;11(3):307-16. doi: 10.1007/s11302-015-9453-8. Epub 2015 May 10.
7
P2X3 receptor expression by HEK cells conditions their survival.HEK 细胞表达 P2X3 受体可调节其存活。
Purinergic Signal. 2012 Jun;8(2):295-300. doi: 10.1007/s11302-011-9285-0. Epub 2011 Dec 8.
8
DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons.DHE 对三叉神经节神经元中 ATP 介导的敏化作用的抑制。
Headache. 2010 Oct;50(9):1424-39. doi: 10.1111/j.1526-4610.2010.01714.x.
9
Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF.偏头痛介质降钙素基因相关肽(CGRP)和神经生长因子(NGF)使痛觉传导P2X3受体致敏的分子机制。
Mol Neurobiol. 2008 Feb;37(1):83-90. doi: 10.1007/s12035-008-8020-5. Epub 2008 May 6.
10
Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats.假定的P2X3/P2X2/3拮抗剂A-317491对环磷酰胺诱导的大鼠膀胱炎的治疗作用。
Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):483-90. doi: 10.1007/s00210-007-0197-z. Epub 2007 Oct 5.